US-based medical device company St. Jude Medical has launched its SyncAV CRT software to enable physicians with new treatment options for heart failure patients.
The SyncAV CRT software, which has also secured approval from the US Food and Drug Administration (FDA), is based on the company’s MultiPoint Pacing technology and features an algorithm which allows the device to work independently and alongside the MultiPoint Pacing Technology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Heart Hospital at Baylor, in Plano, Texas electrophysiology services medical director Dr. Adam Shapira said: “The SyncAV software used alone or with MultiPoint Pacing technology offers the enhanced potential to optimise heart failure therapy for patients who previously did not respond to traditional CRT therapy.
“The SyncAV software also offers the ability for automated setup, which facilitates efficient programming both remotely via Merlin and directly in the office.”
The device adjusts pacing automatically based on real-time changes in a patient’s cardiac condition while providing physicians with an opportunity to improve treatment for patients who have displayed a positive response to the traditional CRT.
St. Jude Medical chief medical officer global clinical affairs vice-president Dr Mark Carlson said: “Approval of the SyncAV CRT technology is important for those patients who are not getting the desired response from traditional cardiac resynchronisation therapy.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe CRT technology issues programmed electrical impulses which resynchronises the lower chambers (ventricles) of the heart to stimulate each ventricle to beat in concert thereby improving the cardiac performance.
